Thelansis

  Triple-negative breast cancer (TNBC) is a heterogeneous disease encompassing a variety of biomarkers or genomic signatures; it accounts for 12% of all breast cancers in the USA. 1- and 2- year survival rates are 75% and 55%, respectively. Prognosis is poor in the advanced stages – median survival of 13.3 months following diagnosis of metastatic TNBC. Emerging therapies are expected to drive patient stratification for biomarker-defined and pathway-specific (subtyping) patient subgroups - an opportunity for a novel agent in relevant specific segments. TNBC is a clinicopathologic, not intrinsic (genomically defined) subgroup, as neither overexpressing ER and PR nor being HER2+ (IHC and/or FISH). Neither hormonal (endocrine) nor HER2-targeted therapies are indicated potential for FastTrack/ breakthrough designation with promising outcomes in the biomarker-driven patient segment. Several PARP inhibitors are in trials; veliparib+carboplatin followed by chemotherapy showed pCR: 52% vs 26%